搜索
期刊论文 更多+

2021年  ▏ 2020年  ▏ 2019年  ▏ 2018年  ▏ 2017年  ▏ 2016年  ▏ 2015年  ▏ 2014年  ▏ 2013年  ▏ 更多


# Co-fisrt author 

* Corresponding author


2020年 更多+

1. Yu Tao, Hon Fai Chan, Bingyang Shi*, Mingqiang Li*, Kam W. Leong*. Light: a magical tool for controlled drug delivery. Advanced Functional Materials 2020, DOI: 10.1002/adfm.202005029.


2. Shuqi Li#, Weiqian Jiang#, Chunxiong Zheng#, Dan Shao, Yilun Liu, Shuqiang Huang, Jing Han, Jianxun Ding*, Yu Tao*, Mingqiang Li*. Oral delivery of bacteria: basic principles and biomedical applications. Journal of Controlled Release 2020, DOI: 10.1016/j.jconrel.2020.09.011.


3. Yu Tao#Mingqiang Li#, Xiangyu Liu, Kam W. Leong, Jean Gautier*, Shan Zha*. Dual-color plasmonic nanosensor for radiation dosimetry. ACS Applied Materials & Interfaces 2020, 12, 22499-22506.


4. Jing Gong#, Hong‐Xia Wang#, Yeh‐Hsing Lao, Hanze Hu, Naazanene Vatan, Jonathan Guo, Tzu‐Chieh Ho, Dantong Huang, Mingqiang Li, Dan Shao, Kam W. Leong*. A versatile nonviral delivery system for multiplex gene‐editing in the liver. Advanced Materials 2020, 2003537.


5. Shaohui Deng#, Xiaoxia Li#, Shuang Liu, Jifeng Chen, Mingqiang Li, Sing Yian Chew, Kam W. Leong*, Du Cheng*. Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects. Science Advances 2020, 6, eabb4005.


6. Jianati Dawulieti, Madi Sun, Yawei Zhao, Dan Shao*, Huize Yan, Yeh-Hsing Lao, Hanze Hu, Lianzhi Cui, Xiaoyan Lv, Feng Liu, Chun-Wei Chi, Yue Zhang, Mingqiang Li, Ming Zhang, Huayu Tian, Xuesi Chen, Kam W. Leong*, Li Chen*. Treatment of severe sepsis with nanoparticulate cell-free DNA scavengers. Science Advances 2020, 6, eaay7148.



7. Yunqing Xiang, Hui Wen, Yue Yu, Mingqiang Li, Xiongfei Fu, Shuqiang Huang*. Gut-on-chip: recreating human intestine in vitro. Journal of Tissue Engineering 2020, DOI: 10.1177/2041731420965318.


8. Rachel L. Mintz, Yeh‐Hsing Lao, Chun‐Wei Chi, Siyu He, Mingqiang Li, Chai Hoon Quek, Dan Shao, Boyuan Chen, Jing Han, Sihong Wang, Kam W. Leong*. CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells. Bioengineering & Translational Medicine 2020, 5, e10152.


地址:广东省广州市天河区 天河路600号

          中山大学  附属第三医院

邮编:510630

 

Copyright © 2021 生物材料与转化医学实验室 版权所有

 

添加微信好友,详细了解产品
使用企业微信
“扫一扫”加入群聊
复制成功
添加微信好友,详细了解产品
我知道了